Related Experiment Videos
Sporadic medulloblastomas contain oncogenic beta-catenin mutations
R H Zurawel1, S A Chiappa, C Allen
1Department of Neurosurgery, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
Abstract:
The beta-catenin, glycogen synthase kinase 3beta (GSK-3beta), and adenomatous polyposis coli (APC) gene products interact to form a network that influences the rate of cell proliferation. Medulloblastoma occurs as part of Turcot's syndrome, and patients with Turcot's who develop medulloblastomas have been shown to harbor germ-line APC mutations. Although APC mutations have been investigated and not identified in sporadic medulloblastomas, the status of the beta-catenin and GSK-3beta genes has not been evaluated in this tumor. Here we show that 3 of 67 medulloblastomas harbor beta-catenin mutations, each of which converts a GSK-3beta phosphorylation site from serine to cysteine. The beta-catenin mutation seen in the tumors was not present in matched constitutional DNA in the two cases where matched DNA was available. A loss of heterozygosity analysis of 32 medulloblastomas with paired normal DNA samples was performed with four microsatellite markers flanking the GSK-3beta locus; loss of heterozygosity with at least one marker was identified in 7 tumors. Sequencing of the remaining GSK-3beta allele in these cases failed to identify any mutations. Taken together, these data suggest that activating mutations in the beta-catenin gene may be involved in the development of a subset of medulloblastomas. The GSK-3beta gene does not appear to be a target for inactivation in this tumor.
Insights
Activating mutations in the beta-catenin gene may contribute to medulloblastoma development. Researchers found specific beta-catenin mutations in a subset of tumors, suggesting a role in cell proliferation pathways.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The adenomatous polyposis coli (APC), beta-catenin, and glycogen synthase kinase 3beta (GSK-3beta) gene products form a network regulating cell proliferation.
- Medulloblastoma, a pediatric brain tumor, is associated with Turcot's syndrome, characterized by germline APC mutations.
- While APC mutations are known in some medulloblastomas, the roles of beta-catenin and GSK-3beta in sporadic medulloblastomas remain unclear.
Purpose of the Study:
- To investigate the involvement of beta-catenin and GSK-3beta gene mutations in the pathogenesis of sporadic medulloblastomas.
- To determine if alterations in these genes contribute to the uncontrolled cell proliferation observed in medulloblastoma.
Main Methods:
- Screening of 67 medulloblastoma samples for beta-catenin mutations.
- Analysis of matched tumor and constitutional DNA to confirm somatic mutations.
- Loss of heterozygosity analysis for the GSK-3beta locus in 32 medulloblastomas.
- Sequencing of the remaining GSK-3beta allele in cases with loss of heterozygosity.
Main Results:
- Beta-catenin mutations were identified in 3 out of 67 medulloblastomas, altering key phosphorylation sites.
- These beta-catenin mutations were somatic, not present in constitutional DNA.
- Loss of heterozygosity at the GSK-3beta locus was observed in 7 tumors, but no mutations were found in the remaining allele.
Conclusions:
- Activating mutations in the beta-catenin gene are implicated in the development of a subset of sporadic medulloblastomas.
- The GSK-3beta gene does not appear to be a primary target for inactivation in medulloblastoma development.
- These findings highlight the critical role of the beta-catenin pathway in medulloblastoma tumorigenesis.